Patents Examined by Matthew P Coughlin
  • Patent number: 11591305
    Abstract: The present invention provides a method for producing fisetin or fisetin derivatives, which is capable of mass production. The method for producing fisetin or fisetin derivatives according to the present invention is capable of mass-producing fisetin or fisetin derivatives without a purification process such as a column chromatography process.
    Type: Grant
    Filed: January 7, 2022
    Date of Patent: February 28, 2023
    Assignee: DAEGU CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong Wook Kang, Min Gi Chu, Seok Ju Lee, Eun Jung Lee
  • Patent number: 11591306
    Abstract: The present invention relates to a vitamin E-based amphipathic compound, a method for producing same, and a method for extracting, solubilizing, stabilizing, or crystallizing a membrane protein using same. By using a compound according to the present invention, not only is an excellent membrane protein extraction and solubilization effect achieved, but the membrane protein can be stably stored for a long period of time in an aqueous solution, and thus the compound can be utilized in analyzing the function and structure of the membrane protein. Moreover, the vitamin E-based amphipathic compounds exhibited superb properties in the visualization of protein compounds through an electron microscope.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: February 28, 2023
    Assignee: Industry-University Cooperation Foundation Hanyang University Erica Campus
    Inventors: Pil Seok Chae, Ehsan Muhammad
  • Patent number: 11583503
    Abstract: The present disclosure relates to a composition sustainable-releasing hydrogen sulfide for promoting wound healing and the method for preparing the same. The composition for promoting wound healing comprises a carrier and a plurality of hydrogen sulfide sustained releasing microspheres, wherein the hydrogen sulfide sustained releasing microspheres comprise a hydrophobic polymer, a surfactant and sodium hydrosulfide.
    Type: Grant
    Filed: March 17, 2021
    Date of Patent: February 21, 2023
    Assignee: BenQ Materials Corporation
    Inventor: Lie-Sian Yap
  • Patent number: 11578084
    Abstract: Novel compounds having a D3 receptor antagonistic effect are provided. The compound represented by Formula (IA)?: wherein A is S or O; R1a is substituted or unsubstituted alkyloxy or the like, R2a to R2d are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R3 is each independently halogen or the like, r is an integer of 0 to 4, R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 14, 2023
    Assignee: Shionogi & Co., Ltd.
    Inventors: Hiroyuki Tobinaga, Koji Masuda
  • Patent number: 11571381
    Abstract: Provided is a method for forming a good fibrous coating on a target surface even in a high-humidity environment when electrostatically spraying is performed directly on the target surface such as skin. A composition for forming a coating of fibers on a target object by electrostatic spraying, comprising the following components (a), (b), (c) and (d): (a) 1 mass % or more and 45 mass % or less of a polymer having a film-forming ability; (b) 45 mass % to 95 mass % of one or more volatile substances selected from the group consisting of an alcohol and a ketone; (c) a conductivity controlling agent to control the conductivity of the composition to 8 ?S/cm or more and 300 ?S/cm or less; and (d) 0.2 mass % or more and 25 mass % or less of water.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: February 7, 2023
    Assignee: KAO CORPORATION
    Inventors: Takahiro Hirano, Takehiko Tohjo, Tatsuya Yoshino
  • Patent number: 11566017
    Abstract: Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH; r represents 0 to 4; each R101 is the same or different when r is 2 or more, and R101 represents a C1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R102 is the same or different when s is 2 or more, and R102 represents a halogen atom or the like; R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: January 31, 2023
    Assignees: RIKEN, JAPANESE FOUNDATION FOR CANCER RESEARCH, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Minoru Yoshida, Hiroyuki Seimiya, Yoko Yashiroda, Kenichi Washizuka, Fumiyuki Shirai, Nobuko Yoshimoto, Junichi Kazami
  • Patent number: 11560354
    Abstract: The present invention relates to a newly identified solvate form of (R)-2-amino-3-phenylpropyl carbamate (APC) hydrochloride, a method of preparing APC hydrochloride, and methods of using the same to treat disorders. The invention further relates to methods of producing APC hydrochloride with increased purity.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: January 24, 2023
    Assignees: Axsome Malta Ltd., SK Biopharmaceuticals Co., Ltd.
    Inventor: Fionn Hurley
  • Patent number: 11560383
    Abstract: Provided is a compound having higher fluorescence quantum yield and higher optical stability than a conventional FLAP and a polymer compound containing the compound. A: seven or eight-membered ring structure, Y1, Y2, Y3: halogen atom or the like, a1: number of Y1, a2: number of Y2, B: number of Y3, 0?m and n?3: when 1?m?3, Y1 may be substituted with a structure portion defined by m, when 1?n?3, Y2 may be substituted with a structure portion defined by n, and B1, B2: Formulas (2-1) to (2-3). C1, C2, C3: structure containing a cyclic hydrocarbon compound, D1, D2, D3: substructure that inhibits aggregation, E1, E2, E3: polymerizable substructure, Z1: hydrogen atom or the like, c: number of substituent groups Z1, Z2, Z3: hydrogen atom or the like, and may form a ring with C2.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: January 24, 2023
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Shohei Saito, Hiroshi Yabu, Hiroya Abe
  • Patent number: 11560368
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 24, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Guoqiang Wang, Ruichao Shen, Jiang Long, Jun Ma, Xuechao Xing, Yong He, Brett Granger, Jing He, Bin Wang, Yat Sun Or
  • Patent number: 11559510
    Abstract: A method for providing a steady state plasma concentration of about 20-400 ng/ml of isoflavonoid compounds comprising the steps of a first rectal administration of the compound in a lipophilic suppository base followed by further rectal administrations no earlier than 4, 8 or 16 hours after the previous rectal administration.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: January 24, 2023
    Assignee: NOXOPHARM LIMITED
    Inventors: Graham Kelly, Kate Porter
  • Patent number: 11560388
    Abstract: This invention provides for compounds of the formula: wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: January 24, 2023
    Inventors: Alan Long, Hannes Fiepko Koolman, Hyoung Ik Lee
  • Patent number: 11534373
    Abstract: A wet wipe that exhibits a novel combination of properties and methods for making such wet wipes are provided.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 27, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Thomas James Klofta, Steven Lee Barnholtz, Christopher Scott Cameron, Mario Castillo, Randall Glenn Marsh, Pamela Marie Morison, Wendy Qin, Jeffrey David Turner
  • Patent number: 11530219
    Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: December 20, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
  • Patent number: 11530200
    Abstract: The present invention relates to compounds of formula (I), wherein Q is selected from O or S; R1 is a 5- or 6-membered heteroaryl group consisting of one or more carbon atoms, and one or more nitrogen and/or oxygen atoms, and substituted with a monovalent, optionally substituted cycloalkyl, cycloalkenyl or heterocyclic group, wherein the 5- or 6-membered heteroaryl group of R1 may optionally be further substituted; R2 is an ?,??-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently an optionally substituted C1-C4 alkyl group.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: December 20, 2022
    Assignee: INFLAZOME LIMITED
    Inventors: Matthew Cooper, David Miller, Jimmy Van Wiltenburg
  • Patent number: 11518757
    Abstract: The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: December 6, 2022
    Assignee: NodThera Limited
    Inventors: David Harrison, Alan Paul Watt, Mark G. Bock
  • Patent number: 11518756
    Abstract: The present invention relates to a selective method for carrying out the Buchwald-Hartwig coupling of biphenyl derivatives.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 6, 2022
    Assignee: UMICORE AG & CO. KG
    Inventors: Lukas J. Goossen, Matthias Gruenberg
  • Patent number: 11510875
    Abstract: Formulations and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed. The formulations generally comprise a TLR4 agonist and a metabolizable oil at a concentration of about 0.01%-1% v/v, wherein the hydrophobic:lipophilic balance (HLB) of the emulsion is greater than about 9.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: November 29, 2022
    Assignee: ACCESS TO ADVANCED HEALTH INSTITUTE
    Inventors: Christopher Fox, Steven G. Reed, Susan Baldwin, Thomas Vedvick
  • Patent number: 11512063
    Abstract: A method for synthesizing functionalized bio-based crosslinkers including forming a first mixture by mixing a bio-based carboxylic acid with an alkaline solution and forming a second mixture containing a functionalized bio-based crosslinker by reacting the bio-based carboxylic acid with a modifier. The modifier includes at least one of an epoxide group and an acrylate group. Reacting the bio-based carboxylic acid with the modifier includes forming a reaction mixture by mixing the first mixture with the modifier and exposing the reaction mixture to at least one of heating, ultrasound radiation, and microwave radiation.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: November 29, 2022
    Inventors: Kourosh Kabiri Bamoradian, Zeinab Karami, Mohammad Jalaloddin Zohuriaan-Mehr
  • Patent number: 11512060
    Abstract: The present invention relates to pharmaceutical compositions of 1,2,4-oxadiazole compounds or a pharmaceutically acceptable salt thereof of formula (I) In the formula Q is O, R1 is the side chain of Ser, R2 is —CO-Thr, R3 is the side chain of Asn or Glu, and R4, R5 and R6 are each H.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: November 29, 2022
    Assignee: Aurigene Discovery Technologies Limited
    Inventors: Pottayil Govindan Nair Sasikumar, Muralidhara Ramachandra, Seetharamaiah Setty Sudarshan Naremaddepalli
  • Patent number: 11498925
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: November 15, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Andrew Wasmuth, Donald W. Landry